Fig. 1 · Structure

Documents & Downloads

Cinobufagin

Cat. No. A12032 CAS 470-37-1
Cinobufagin is a specific Na+/K+-ATPase inhibitor. About as active as ouabain

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Cinobufagin Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Cinobufagin from 3 published references. In vitro models include HCT-116 CRC cells; H1299 cells. In vivo models include A549 NSG xenograft mouse models.

Cinobufagin In Vitro Studies

In HCT-116 CRC cells, Cinobufagin inhibited cell survival, with a half-maximal inhibitory concentration below 50 ng/mL at 48 and 72 hours. In H1299 cells, Cinobufagin significantly increased ROS levels relative to control cells in the absence of NAC, and NAC pretreatment significantly blocked these effects. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced survival of colorectal cancer cells

Cell-based study · HCT-116 CRC cells [1]

CBG's IC50, the concentration that inhibited 50% of HCT-116 cell survival, was less than 50 ng/mL at 48 and 72 hours.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT cell viability assayIC50 less than 50 ng/mL at 48 and 72 hours[1]

Literature-Reported Treatment Conditions

Treatment concentration
1-250 ng/mL
Exposure duration
48 and 72 hours
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Cinobufagin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Cinobufagin (CBG) exerts potent cytotoxic and anti-proliferative activity against human CRC cells (S1, S2, S3); MATERIALS AND METHODS > Methyl thiazol tetrazolium (MTT) assay (S79); Figure 1 legend (S112)

MTT cell viability assay: MTT cell viability assay; comparator: untreated control group — RESULTS > Cinobufagin (CBG) exerts potent cytotoxic and anti-proliferative activity against human CRC cells (S2, S3)

Increased reactive oxygen species in lung cancer cells

Cell-based study · H1299 cells [2]

Levels of ROS in the H1299 cells treated with 1 and 2μM CB were significantly increased from 6.05% to 17.90% and 29.66%, as compared to the control cells. These effects were significantly blocked when the cells were pretreated with 5 mM NAC.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The generation of ROS was then analyzed by flow cytometry.ROS levels 1 and 2μM CB, absence of 5 mM NAC: from 6.05% to 17.90% and 29.66%[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 2 μM
Exposure duration
24 hours of treatment
Vehicle
Dimethyl Sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Cinobufagin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Treatments of CB leads to the generation of reactive oxygen species (ROS) and disruption of the mitochondrial transmembrane potential (MMP) through an intrinsic mitochondrial apoptosis pathway in human NSCLC cell lines (S34, S35); MATERIALS AND METHODS > Cell lines, antibodies, and reagents (S59); MATERIALS AND METHODS > Determination of ROS and MMP (S99, S100, S103)

The generation of ROS was then analyzed by flow cytometry.: The generation of ROS was then analyzed by flow cytometry.; comparator: control cells — RESULTS > Treatments of CB leads to the generation of reactive oxygen species (ROS) and disruption of the mitochondrial transmembrane potential (MMP) through an intrinsic mitochondrial apoptosis pathway in human NSCLC cell lines (S34, S35); MATERIALS AND METHODS > Determination of ROS and MMP (S99, S103)

Cinobufagin In Vivo Studies

In A549 NSG xenograft mice, intraperitoneal Cinobufagin produced no change in tumor growth at the low dosage and inhibited growth at the middle and high dosages, with compound effects isolated against vehicle. In GL261 tumor-bearing mice, intraperitoneal Cinobufagin alone inhibited tumor growth and prolonged survival compared with vehicle control. [2,3]

Tumor Growth in A549 Xenograft Mice

Animal study · A549 NSG xenograft mouse models (n = 10 mice/each group) [2]

In A549 NSG xenograft mice, intraperitoneal Cinobufagin treatment did not change tumor growth at 1.5 mg/kg/day, significantly inhibited growth at 5 mg/kg/day, and dramatically inhibited growth at 10 mg/kg/day. Compound effects were isolated by comparison with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor size was measured using a Vernier caliper every day in the two longest dimensions.Reported result Although treatment with a low dosage of CB (1.5 mg/kg/day) by intraperitoneal (IP) injection did not change xenograft tumor growth, there was significant inhibition of tumor growth in treatment with a middle dosage of CB (5 mg/kg/day), as compared to that from an effective dosage of platinum drugs (Figure 2A). Notably, the tumor growth was dramatically inhibited in treatment with high dosage of[2]

Conditions shared by the study groups

Route
intraperitoneal (IP) injection
Treatment course
every 5 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cinobufagin 1.5, 5.0, and 10.0 mg/kg/dayvehicle controlAlthough treatment with a low dosage of CB (1.5 mg/kg/day) by intraperitoneal (IP) injection did not change xenograft tumor growth, there was significant inhibition of tumor growth in treatment with a middle dosage of CB (5 mg/kg/day), as compared to that from an effective dosage of platinum drugs (Figure 2A). Notably, the tumor growth was dramatically inhibited in treatment with high dosage of CB (10 mg/kg/day).[2]
Cinobufagin 1.5, 5.0, and 10.0 mg/kg/day
Model: A549 NSG xenograft mouse models (n = 10 mice/each group)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Cinobufagin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > CB dose-dependently inhibits the tumor growth of human NSCLC cell lines (S10, S11); MATERIALS AND METHODS > Cell lines, antibodies, and reagents (S59); MATERIALS AND METHODS > Xenogeneic transplantation (S79, S80, S81); Figure 2 legend (S130, S132, S133)

Tumor size was measured using a Vernier caliper every day in the two longest dimensions.: Tumor size was measured using a Vernier caliper every day in the two longest dimensions.; comparator: vehicle control — RESULTS > CB dose-dependently inhibits the tumor growth of human NSCLC cell lines (S10, S11); MATERIALS AND METHODS > Xenogeneic transplantation (S81)

Cinobufagin 1.5, 5.0, and 10.0 mg/kg/day · RESULTS > CB dose-dependently inhibits the tumor growth of human NSCLC cell lines (S10, S11); MATERIALS AND METHODS > Xenogeneic transplantation (S80)

Tumor Growth and Survival in Glioma Models

Animal study · GL261 tumors; C57BL/6J mice; N = 4–5 mice/group [3]

In GL261 tumor-bearing mice, intraperitoneal Cinobufagin treatment alone inhibited tumor growth and prolonged survival, with compound effects isolated by comparison with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantitative bioluminescence analysisReported result cinobufagin alone can inhibit tumor growth and prolong the survival of GL261- and CT2A-bearing mice[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
starting on day 6 post-implantation, every other day for a total of five doses
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cinobufagin 5 mg/kgvehicle controlcinobufagin alone can inhibit tumor growth and prolong the survival of GL261- and CT2A-bearing mice[3]
Cinobufagin 5 mg/kg
Model: GL261 tumors; C57BL/6J mice; N = 4–5 mice/group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Cinobufagin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mouse models and therapeutic trials (S47, S53, S54); Materials and methods > Bioluminescent monitoring (S58); Results > Cinobufagin induces immunogenic PANoptosis and potentiates GBM to anti-PD-1 therapy (S207); Fig. 9 legend (S296, S297, S298, S299)

Quantitative bioluminescence analysis: Quantitative bioluminescence analysis; comparator: vehicle control — Results > Cinobufagin induces immunogenic PANoptosis and potentiates GBM to anti-PD-1 therapy (S207); Fig. 9 legend (S298)

Cinobufagin 5 mg/kg · Materials and methods > Mouse models and therapeutic trials (S54); Results > Cinobufagin induces immunogenic PANoptosis and potentiates GBM to anti-PD-1 therapy (S207)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 470-37-1
Formula C26H34O6
Molecular Weight 442.6
SMILES
CC(=O)O[C@@H]1[C@@H]([C@]2(CC[C@H]3[C@H]([C@@]24[C@@H]1O4)CC[C@H]5[C@@]3(CC[C@@H](C5)O)C)C)C6=COC(=O)C=C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 94 mg/mL (212.4 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cinobufagin Research References

  1. [1] Lu XS, Qiao YB, Li Y, et al. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent. Oncotarget (2017). PMID: 27894091 DOI: 10.18632/oncotarget.13519 Source material
  2. [2] Zhang G, Wang C, Sun M, et al. Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells. Oncotarget (2016). PMID: 26959116 DOI: 10.18632/oncotarget.7898 Source material
  3. [3] Cai Y, Xiao H, Xue S, et al. Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy. J Exp Clin Cancer Res (2025). PMID: 39901195 DOI: 10.1186/s13046-025-03301-1 Source material

Added to your cart

View Cart Checkout
Loading...